Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Sep 10:8:24-27.
doi: 10.1016/j.nmni.2015.09.001. eCollection 2015 Nov.

Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF

A Y Dagnra  1 , K D Mlaga  2 , K Adjoh  3 , E Kadanga  1 , K Disse  3 , T Adekambi  4
Affiliations

Prevalence of multidrug-resistant tuberculosis cases among HIV-positive and HIV-negative patients eligible for retreatment regimen in Togo using GeneXpert MTB/RIF

A Y Dagnra et al. New Microbes New Infect. .

Abstract

Drug-resistant tuberculosis (TB) is emerging as an important health problem in Togo. From sputum of previously treated TB patients, multidrug-resistant (MDR) TB was diagnosed in 24% (10/42) patients via GeneXpert MTB/RIF compared to 25% (6/24) patients via conventional drug susceptibility testing (BACTEC MGIT 960 system). The agreement between these two methods to detect MDR-TB is excellent. However, GeneXpert MTB/RIF offers the advantage of rapidly detecting Mycobacterium tuberculosis complex in sputum samples in instances where the cultures are negative (33%, 14/42) or contaminated (9.5%, 4/42). GeneXpert MTB/RIF permitted us to estimate the prevalence of MDR-TB in previously treated TB patients and to improve TB diagnostics among HIV-positive and -negative patients in Togo, where culturing M. tuberculosis complex from sputum samples is challenging.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Distribution of drug susceptibility testing profile based on BACTEC MGIT 960 system.
See this image and copyright information in PMC

References

    1. World Health Organization . World Health Organization; Geneva, Switzerland: 2012. Global tuberculosis report, 2012.http://apps.who.int/iris/bitstream/10665/75938/1/9789241564502_eng.pdf Available at:
    1. Verhoef J. The BCG controversy. Int J Antimicrob Agents. 1994;4:291–295. - PubMed
    1. Gu C. 1996. Mycobacterium tuberculosis: BCG et stratégies vaccinales; pp. 107–116.http://www.ipubli.inserm.fr/bitstream/handle/10608/208/?sequence=17 Available at:
    1. Zhang Y., Yew W. Mechanisms of drug resistance in Mycobacterium tuberculosis. Int J Tuberc Lung Dis. 2009;13:1320–1330. - PubMed
    1. WHO/HTM/TB . 2008. Anti-Tuberculosis Drug.

LinkOut - more resources